Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis

Bianca Rocca, Carlo Patrono, Steen Husted, Ramzi A. Ajjan, Jurrien Ten Berg, Marco Cattaneo, Jean-Philippe Collet, Raffaele De Caterina, Keith A. A. Fox, Sigrun Halvorsen, Kurt Huber, Elaine M. Hylek, Gregory Y. H. Lip, Gilles Montalescot, Joao Morais, Freek W. A. Verheugt, Lars Wallentin, Thomas W. Weiss, Robert F. Storey

Risultato della ricerca: Contributo in rivistaArticolo in rivistapeer review

138 Citazioni (Scopus)

Abstract

Contemporary medicine is shifting towards person rather than disease-oriented care.1With increasing life expectancy and the ageing of baby boomers, the proportion over 60 years is growing faster than the overall population, with worldwide estimates reaching 2 billion by 2050 (http://www.un.org/esa/population/publications/ worldageing19502050).2 In parallel, acute coronary syndromes (ACS) and atrial fibrillation (AF)—the most frequent indications for dual platelet inhibition or anticoagulation—occur mostly in older patients.2 – 6 There is general agreement that people ≥75 years can be defined ‘elderly’; however, cutoffs as low as 65 years have been applied to important clinical datasets and risk scores.3,7 – 10
Lingua originaleEnglish
pagine (da-a)3238-3249
Numero di pagine12
RivistaEuropean Heart Journal
Volume36
DOI
Stato di pubblicazionePubblicato - 2015

Keywords

  • antithrombotic therapy
  • elderly

Fingerprint Entra nei temi di ricerca di 'Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis'. Insieme formano una fingerprint unica.

Cita questo